Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $522.55 million. The enterprise value is $1.35 billion.
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 113.11 million shares outstanding. The number of shares has decreased by -2.43% in one year.
| Current Share Class | 113.11M |
| Shares Outstanding | 113.11M |
| Shares Change (YoY) | -2.43% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 91.86% |
| Float | 110.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.09 |
| PS Ratio | 0.22 |
| Forward PS | 0.16 |
| PB Ratio | 1.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.82 |
| P/OCF Ratio | 8.05 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 24.05, with an EV/FCF ratio of 38.21.
| EV / Earnings | n/a |
| EV / Sales | 0.58 |
| EV / EBITDA | 24.05 |
| EV / EBIT | n/a |
| EV / FCF | 38.21 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 2.61.
| Current Ratio | 1.26 |
| Quick Ratio | 1.21 |
| Debt / Equity | 2.61 |
| Debt / EBITDA | 16.67 |
| Debt / FCF | 27.60 |
| Interest Coverage | -0.44 |
Financial Efficiency
Return on equity (ROE) is -83.57% and return on invested capital (ROIC) is -2.51%.
| Return on Equity (ROE) | -83.57% |
| Return on Assets (ROA) | -0.86% |
| Return on Invested Capital (ROIC) | -2.51% |
| Return on Capital Employed (ROCE) | -2.07% |
| Weighted Average Cost of Capital (WACC) | 7.13% |
| Revenue Per Employee | $557,822 |
| Profits Per Employee | -$120,879 |
| Employee Count | 4,200 |
| Asset Turnover | 1.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Evolent Health has paid $3.07 million in taxes.
| Income Tax | 3.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.53% in the last 52 weeks. The beta is 1.02, so Evolent Health's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +10.53% |
| 50-Day Moving Average | 4.24 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 51.50 |
| Average Volume (20 Days) | 1,699,596 |
Short Selling Information
The latest short interest is 10.61 million, so 9.38% of the outstanding shares have been sold short.
| Short Interest | 10.61M |
| Short Previous Month | 12.91M |
| Short % of Shares Out | 9.38% |
| Short % of Float | 9.56% |
| Short Ratio (days to cover) | 5.85 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.34 billion and -$507.69 million in losses. Loss per share was -$4.52.
| Revenue | 2.34B |
| Gross Profit | 350.28M |
| Operating Income | -30.53M |
| Pretax Income | -504.63M |
| Net Income | -507.69M |
| EBITDA | 56.02M |
| EBIT | -30.53M |
| Loss Per Share | -$4.52 |
Full Income Statement Balance Sheet
The company has $148.26 million in cash and $973.05 million in debt, with a net cash position of -$824.80 million or -$7.29 per share.
| Cash & Cash Equivalents | 148.26M |
| Total Debt | 973.05M |
| Net Cash | -824.80M |
| Net Cash Per Share | -$7.29 |
| Equity (Book Value) | 372.85M |
| Book Value Per Share | 3.30 |
| Working Capital | 127.18M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $64.88 million and capital expenditures -$29.62 million, giving a free cash flow of $35.26 million.
| Operating Cash Flow | 64.88M |
| Capital Expenditures | -29.62M |
| Depreciation & Amortization | 86.55M |
| Net Borrowing | -105.42M |
| Free Cash Flow | 35.26M |
| FCF Per Share | $0.31 |
Full Cash Flow Statement Margins
Gross margin is 14.95%, with operating and profit margins of -1.30% and -21.67%.
| Gross Margin | 14.95% |
| Operating Margin | -1.30% |
| Pretax Margin | -21.54% |
| Profit Margin | -21.67% |
| EBITDA Margin | 2.39% |
| EBIT Margin | -1.30% |
| FCF Margin | 1.50% |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.43% |
| Shareholder Yield | 2.43% |
| Earnings Yield | -97.87% |
| FCF Yield | 6.75% |
Analyst Forecast
The average price target for Evolent Health is $6.00, which is 29.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 29.87% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 25.66% |
| EPS Growth Forecast (3Y) | 80.18% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 0.41 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.41 |
| Piotroski F-Score | 4 |